What Dentinox Treats: Main Uses and Benefits

This class of medication is generally used to help with symptoms related to excess gas and trapped wind. The medication is considered relevant for the symptomatic management of conditions characterized by symptoms of physical discomfort in the pediatric population.

It is commonly used across therapeutic domains involving infant colic, abdominal bloating, and griping pains. These are conditions where symptoms may become intense or disruptive due to internal pressure. The product's therapeutic benefit helps ease the overall symptom burden during episodes of distress. It is often applied during phases when symptoms become more noticeable, such as after feeding, or during acute flare-ups.

This supportive function is relevant, as it may assist with maintaining a sense of stability when symptoms are more noticeable. The relief focuses on symptoms related to physical discomfort, supporting the baby during difficult episodes.

---

Quick Fact: Relief for Gastrointestinal Pressure

---

Easing Distress and Abdominal Pressure

Dentinox is applied across domains where additional symptomatic support is needed, primarily addressing intense, inconsolable crying and signs of noticeable physiological strain caused by trapped wind. The benefit is centered on providing support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.

The eligibility for Dentinox Infant Colic Drops is defined strictly by its regulatory license, which limits its use to a specific population and outlines absolute prohibitions and restrictions.

---

Approved Population

This medicine is formally licensed for use only in the pediatric population. The approved age group is infants from birth onwards, encompassing newborns and older babies. Use is not established or licensed for older children, adolescents, adults, or older adults, as the product is indicated solely for infant colic.

---

Contraindications and Restrictions

Use of Dentinox is contraindicated and the product must not be administered to the following groups:

• Infants with known hypersensitivity to the active ingredient, Activated Dimeticone (Simethicone), or any other component in the formulation.
• Patients with specific rare hereditary metabolic disorders, including fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

Additionally, a specific conditional exclusion applies: Infants who are currently being treated for a thyroid disorder should not be given the medicine. Regulatory warnings advise seeking professional medical consultation, as the active substance may interfere with the absorption of concurrent thyroid medication.

Interactions with other medicines and products

Dentinox Infant Colic Drops contain the active ingredient Simethicone, which is classified as a non-systemic antiflatulent agent. This means the substance is not absorbed into the bloodstream or involved in the body’s metabolic pathways, which dictates a minimal risk for conventional drug-drug interactions.

Officially documented information confirms that no broad categories of medicinal products or common consumables are contraindicated for co-administration due to interaction risk. Furthermore, regulatory sources document no known interactions with food, drinks, or alcohol.

Official Interaction Profile

The interaction profile is predominantly characterized by the absence of systemic effects. The following specific interaction patterns are documented in authoritative sources:

Interaction Type	Officially Documented Statement
Pharmacokinetic Profile	No involvement in major Cytochrome P450 (CYP) enzyme systems due to lack of systemic absorption.
Exposure Modification	Co-administration with Carbamazepine may result in increased plasma concentrations of Carbamazepine. This is a documented exposure-altering interaction that can lead to potential toxicity.
Contraindication	The only formal restriction is contraindication in cases of known hypersensitivity to simethicone or any component of the formulation.

No mandatory time separation windows are specified for the co-administration of this product with other medicines in official labeling. The interaction structure is solely defined by its localized effect in the gastrointestinal tract.

Surface-Active Antifoaming

This domain involves the active ingredient activated dimeticone, a surface-active substance. It modulates the physical properties of the gastrointestinal contents by changing the surface tension of trapped gas bubbles, facilitating their coalescence into larger bubbles. This physicochemical effect allows for the subsequent dispersal or passage of the gas.

---

Local Neural Signal Blockade

This domain is primarily mediated by lidocaine, a local anesthetic in the teething gel formulation. Its mechanism involves blocking the initiation and conduction of nerve impulses by inhibiting the influx of sodium ions through voltage-gated sodium channels in the nerve cell membrane. This action results in a transient, localized alteration of afferent nerve impulse transmission in the area of application.

The usage of Dentinox Infant Colic Drops is defined by established guidelines, which govern the route, dose, and frequency for the intended patient population. As an oral suspension, the medicine is administered via the oral route.

Official Administration Guidelines

The administration protocol is standardized for infants, requiring the user to adhere to specific volume and frequency constraints as outlined in the product information.

Instruction	Detail
Route of Administration	Oral
Dosing Schedule	Single dose volume is 2.5 ml. The strength is 21 mg Activated Dimeticone per 2.5 ml dose.
Timing and Frequency	Administer with or after each feed. Do not exceed 6 doses in any 24-hour period.
Age-Group Rule	Suitable for use in infants from birth onwards.

---

Procedural Structure

The official instructions establish a fixed procedural sequence to ensure accurate administration:

1. The bottle must be shaken well before use to ensure the active ingredient is suspended evenly.
2. The prescribed dose of 2.5 ml must be measured accurately using the provided oral dosing syringe.
3. The dose is then administered orally, either directly from the syringe or mixed into the infant's bottle feed.

This protocol defines a precise use pattern tied to the infant's feeding schedule, ensuring the total daily intake of Activated Dimeticone does not exceed the maximum limit. The medicine is intended for use in a symptom-driven, intermittent manner.

Research evidence / Overview of studies for Dentinox

Evidence for Use in Infant Colic and Excessive Crying

Research exploring the use of Simethicone for infant colic has primarily relied on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time, typically including infants under six months old who were experiencing excessive, inconsolable crying. Researchers measured outcomes related to physical discomfort by monitoring the change in the mean daily crying duration and recording patient-reported outcomes describing perceived discomfort.

Findings across the available studies have been inconsistent. Some trials reported patterns observed in the studies that tracked the evolution of symptoms, while other large systematic reviews described measurements of crying duration that were comparable between the groups receiving Simethicone and those receiving a placebo. The evidence derived from these research contexts involving fluctuating or unstable symptoms often highlights changes measured during the study period that are small or inconsistent across different trials. These findings help contextualize how patients reported their experience, but certainty remains low.

Evidence for Use in Symptoms of Excess Gas and Bloating

Research explored the use of Simethicone for conditions characterized by fluctuating or episodic manifestations of gas and bloating in adults and adolescents. Studies explored the effect on patient-reported outcomes describing perceived discomfort, such as the severity of abdominal fullness, pressure, and distension. Research examined how symptoms evolved in the observed populations, with studies conducted during periods of increased symptom activity.

Trials monitored patient-reported outcomes for symptoms of abdominal discomfort and fullness over short and intermediate treatment durations. Findings sometimes described changes in patient-reported symptom scores compared to baseline measurements. However, some evidence is derived from studies where the agent was evaluated in combination with other treatments. Data for certain groups, such as those with chronic conditions or the elderly, remain insufficient.

What is Still Uncertain: Research Gaps and Limitations

The broader evidence landscape highlights certain key limitations. For instance, in colic trials, high placebo response rates were observed, which must be considered when evaluating the research. Furthermore, comparative evidence is lacking against many non-pharmacological interventions for managing infant discomfort. Generally, follow-up durations were limited, and long-term effects are not fully established.

Key Studies & References

1. Simethicone Drug Information - FDA Labeling and Monographs (supporting regulatory scope and mechanism)

Common questions about Dentinox (FAQ)

Q: What is the main purpose of Dentinox?

According to official product information, Dentinox is intended to provide temporary relief from pain and soreness associated with teething in infants. It contains ingredients recognized as a mild analgesic and a mild antiseptic to help soothe the gums during the teething process.

Q: Is Dentinox a gel or a liquid?

Regulatory documents indicate that Dentinox is formulated as an oral liquid. This liquid preparation is designed for application directly onto the infant's gums to deliver localized relief.

Q: Can I use Dentinox for other types of mouth pain not related to teething?

Official information states that Dentinox is specifically indicated for teething pain in babies. Regulatory sources state the product is not indicated for other forms of mouth pain or oral conditions.

Q: Does Dentinox contain a local anesthetic?

Yes, regulatory sources confirm that Dentinox contains a mild local anesthetic ingredient. This component is included in the formulation to help provide temporary relief from the pain associated with erupting teeth.

Q: How should I store Dentinox?

According to the official product information, Dentinox should be stored at a temperature below 25°C. It is also specified that the liquid must be kept in its original packaging and out of the sight and reach of children.

Q: How long can I use Dentinox after opening the bottle?

The official product information specifies that Dentinox should be discarded 3 months after first opening the bottle. It is important to discard the product after this time to align with official label guidance.

Q: Can I mix Dentinox with water or milk?

Regulatory documents state that Dentinox should be applied undiluted directly to the gums. The product is officially intended for direct application to the gums and should not be mixed with liquids like water, milk, or food.

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of Dentinox Infant Colic Drops.

Storage Conditions

Requirement	Official Instruction
Temperature Limit	Do not store above 25 °C.
Shelf-Life	Do not use after the expiry date shown on the carton and bottle.
Child Safety	Keep out of the sight and reach of children.
Handling	Shake the bottle before use.

---

Disposal Instructions

To protect the environment, the medicine should not be disposed of in waste-water or with household trash. Unused or expired drops must be disposed of as directed by a pharmacist.